Office: South San Francisco, CA

Executive Assistant:
Christine Esguerra
(650) 238-5055

Nicholas J. Simon, MBA
Managing Director

Nicholas Simon has been a Managing Director of Clarus since the firm’s inception in 2005. Prior to Clarus, Mr. Simon was a General Partner at MPM Capital, a healthcare venture capital firm.  He has over 20 years of operating and investment experience in the biopharmaceutical industry including Genentech from 1989 to 2000 where he was Vice President of Business and Corporate Development.

Mr. Simon received a BS degree in microbiology from the University of Maryland and an MBA from Loyola University. 

Mr. Simon is a Trustee at The J David Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco.

Current Board Seats

Previous Board Seats

Achillion (NASDAQ:ACHN)

Avanir Pharmaceuticals (NASDAQ:AVNR)

Barrier Therapeutics (acquired by Stiefel Laboratories)

Biovitrum AB (STO:SOBI)

CoMentis, Inc.

Cotherix (acquired by Actelion)

InterMune (NASDAQ:ITMN)

Pearl Therapeutics,Inc. (acquired by AstraZeneca)

Quatrx Pharmaceuticals

Rigel (NASDAQ:RIGL)

Sangstat (acquired by Genzyme)

Clarus Board Seats

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Nicholas J. Simon

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Achillion is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, small molecule inhibitors targeting infectious disease. Pipeline programs include a first-in-class HCV replicase inhibitor partnered with Gilead and an HCV protease inhibitor. Additional drug candidates target treatment of HIV and bacterial infections.

Achillion Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Public
Team: Nicholas J. Simon
Dennis Henner
Emmett Cunningham

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR)

Avanir Pharmaceuticals (Nasdaq:AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir’s products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease. Zenvia™ is Avanir's lead product candidate for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder (IEED).

Avanir Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Nicholas J. Simon
Dennis Henner

CoMentis, Inc.

CoMentis, Inc. is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, AMD and cognitive disorders.  The company has two fundamental technology platforms:  (i) beta-secretase inhibitors for the treatment of Alzheimer’s disease; and (ii) nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Royalty Interest
Team: Robert W. Liptak
Scott Requadt
Nicholas J. Simon

Edev

Edev is a special purpose vehicle that has entered into an R&D project financing relationship with an undisclosed pharma company to finance multiple Phase 3 clinical trials for additional indications of an already-approved drug.

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Private
Team: Nicholas J. Simon

Gritstone Oncology

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. Gritstone Oncology is headquartered in the San Francisco Bay Area with certain key functions located in Cambridge, MA. Gritstone Oncology launched in October 2015 with a Series A financing of $102 million

Gritstone Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Royalty Interest
Team: Scott Requadt
Nicholas J. Simon

Imbruvica

Imbruvica is an oral BTK-inhibitor currently under development by Pharmacyclics and J&J for a wide variety of B-cell malignancies, including chronic lymphocytic leukemia(CLL) and mantle cell lymphoma (MCL). It is currently in 8 pivotal trials and multiple Ph 2 trials for various relapsed/refractory and front line settings. The drug has been granted three breakthrough designations by the FDA and was approved for relapsed/refractory MCL in November 2013.

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Scott Requadt
Nicholas J. Simon
Dennis Henner

Intercept Pharmaceuticals (NASDAQ: ICPT)

Intercept is focused on the development and commercialization of novel, small molecule therapeutics to treat chronic liver disease by leveraging its expertise in bile acid chemistry.  Its lead candidate, obaticholic acid (OCA), is an FXR agonist that is currently in pivotal trials for primary biliary cirrhosis (PBC), a chronic autoimmune liver disease.  OCA has received orphan designation for PBC in both the US and Europe.  OCA is also being evaluated in an NIH-sponsored trial for non-alcoholic steatohepatitis (NASH).

Intercept Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Private
Team: Nicholas J. Simon
Dennis Henner

Lycera Corporation

Lycera is an early stage biotechnology company developing first in class small molecule drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.  Lycera’s pipeline includes proprietary small molecules against two novel targets, a mitochondrial molecule that  is central to lymphocyte bioenergetics and a nuclear hormone receptor that modulates the Th17 pathway.  Lycera’s small molecule drugs have the potential for best in class oral efficacy without the adverse effects of current immunosuppressive agents.

Lycera Website

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Public
Team: Nicholas J. Simon

Neothetics (NASDAQ: NEOT)

Neothetics is a clinical-stage company developing therapeutics for the aesthetics market. Their initial focus is on non-surgical localized fat reduction and body contouring. The Company’s lead drug candidate is for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company has completed Phase 2 development for LIPO-202 and plans to launch Phase 3 trials in early 2015.

Neothetics Website

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Defined Exit
Team: Nicholas J. Simon
Nicholas Galakatos

Nuvelution Pharma, Inc.

Nuvelution leverages its extensive knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market.

Nuvelution Pharma

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Nicholas J. Simon
Kurt C. Wheeler
Emmett Cunningham

Pearl Therapeutics acquired by AstraZeneca June 2013

Pearl Therapeutics, Inc. is a privately-held company focused on improving the treatment and prevention of widely prevalent respiratory disorders.  Pearl has licensed a suite of particle technologies from Nektar Therapeutics, Inc. to rapidly advance their product candidates through development.

Fund: Clarus Lifesciences I, L.P.
Sector: Medical Device
Type: Public
Team: Nicholas J. Simon
Kurt C. Wheeler

Sientra, Inc. (NASDAQ: SIEN)

Sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market. In April 2007, Sientra secured $85 million in a Series B financing co-led by Clarus Ventures.

Sientra Website